Adjusted net income for Q2 was $20.5 million or $0.26 per share, compared to $19.3 million or $0.25 per share in the prior year quarter.
Net debt increased to $1.9 billion at June 30, 2025, primarily due to $100 million cash paid to terminate the Rotech acquisition, with operating cash flow improving to $38 million in Q2.
Second quarter 2025 revenue was $682 million, up 3.3% year-over-year, with adjusted EBITDA of $96.6 million representing a 14.2% margin, improved from 13.8% in Q2 2024.
Year-to-date revenue reached $1.36 billion, a 4.5% increase over the first half of 2024, driven by strong growth in sleep, ostomy, and urology categories.
Adjusted free cash flow was $2.5 billion for the year, $500 million above expectations.
Cardinal Health grew operating earnings by 19% in Q4 and 15% for fiscal year 2025, with EPS growth of 13% in Q4 and over 9% for the year.
Fiscal year 2025 revenue decreased 2% to $223 billion due to contract expiration but increased 18% excluding it; operating earnings grew 15% to $2.8 billion.
GMPD segment revenue grew 3% to $3.2 billion with a record Q4 segment profit of $70 million.
Gross profit grew 17% to $2.2 billion in Q4, with a 50 basis point improvement in rate due to favorable product, customer, and business mix.
Other growth businesses saw 37% revenue growth to $1.6 billion and 44% profit growth to $160 million in Q4.
Pharma segment revenue was flat at $55.4 billion in Q4 but increased 22% excluding contract expiration; segment profit grew 11% to $535 million.
SG&A increased 16% to $1.5 billion in Q4, primarily due to acquisitions; on an organic basis, SG&A grew 4%.
Total company revenue was flat at $60.2 billion in Q4, but adjusted for a customer contract expiration, revenue increased 21%.
Dafinchi